Adipo Therapeutics was founded to realize the potential of a novel therapeutic approach of inducing browning of adipose tissues to treat people with type 2 diabetes and obesity. Adipo was founded by Meng Deng, PhD, a faculty fellow of Entrepreneurial Leadership Academy at Purdue University, after he completed NSF I-Corps in December 2016 to validate market niche for his innovation involving development of bioengineered polymeric nanoparticles to induce local browning of white fat through inhibition of Notch signaling, leading to weight loss and improved glucose control in animal models. Adipo has grown to continue the development, testing and commercialization of this technology, licensed through the Purdue Research Foundation Office of Technology Commercialization, as a novel approach to treating diabetes and obesity. Adipo’s efforts are directed by an inspired team of experienced pharmaceutical leaders in diabetes, regulatory affairs, manufacturing, pharmacology, drug development and commercialization.